RMD Open

Prevalence, incidence, mortality and causes of death in a large cohort of patients with rheumatoid arthritis: an Italian population-based study

Objective Rheumatoid arthritis (RA) is the most common form of inflammatory arthritis and primarily affects the joints. While ...
RMD Open

Cellular and molecular basis of neuropathic pain

Neuropathic pain is a devastating type of pain that significantly reduces the quality of life of affected people.
RMD Open

Effect of targeted therapies on pulmonary function in rheumatoid arthritis-associated interstitial lung disease: a systematic review and meta-analysis

Introduction Interstitial lung disease (ILD) is a serious extra-articular manifestation of rheumatoid arthritis (RA) associated with increased morbidity and mortality. The pulmonary safety of biologic ...
RMD Open

Autoantibody biomarkers and first-line therapy response in RA: findings from the CAP48 cohort

Objective A panel of antibodies against three antigens, University Hasselt (UH)-rheumatoid arthritis (RA).305, 318 and 329, has been associated with lack of response to first-line therapy in the Care ...
rmdopen.bmj

Active discopathy: a clinical reality

In the late 1980s, the description by Modic and colleagues of elementary discovertebral changes detected on MRI (Modic classification) suggested for the first time a possible correlation between ...
rmdopen.bmj

Low rates of remission with methotrexate monotherapy in rheumatoid arthritis: review of randomised controlled trials could point towards a paradigm shift

Treatment of rheumatoid arthritis (RA) has improved substantially during the last decades, mainly due to the development and introduction in everyday practice of new, highly efficacious, ...
rmdopen.bmj

Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme

Objective Tofacitinib is an oral Janus kinase (JAK) inhibitor for the treatment of rheumatoid arthritis (RA). We report the largest integrated safety analysis of tofacitinib, as of March 2017, using ...
rmdopen.bmj

Prevalence and anatomical distribution of MRI lesions in axSpA and differences between patients with and without peripheral involvement: results from the ASAS classification cohort

Objective To evaluate the prevalence and anatomical distribution of inflammatory and structural MRI lesions in axial spondyloarthritis (axSpA) and compare these between patients with isolated axial ...
rmdopen.bmj

Longitudinal association of early axial spondyloarthritis status at the time of diagnosis with disease activity over time: 10-year results from the GESPIC cohort

Objective Recently, the definition for ‘early axial spondyloarthritis (axSpA)’ was developed by the Assessment of SpondyloArthritis international Society (ASAS), including ≤2 years of axial symptoms ...
rmdopen.bmj

The MIDORA trial: a phase II, randomised, double-blind, placebo-controlled, mechanistic insight and dosage optimisation study of the efficacy and safety of dazodalibep in ...

Objectives To evaluate the safety, efficacy and response duration of four different dosing regimens of dazodalibep (DAZ), a non-antibody biological antagonist of CD40L, in patients with rheumatoid ...
rmdopen.bmj

Cost-effectiveness of proactive therapeutic drug monitoring of maintenance infliximab treatment in patients with immune-mediated inflammatory diseases: results from a ...

Objective Proactive therapeutic drug monitoring (pTDM) intends to optimise tumour necrosis factor (TNF) inhibitor treatment through regular assessment of drug and antidrug antibody levels, enabling ...
rmdopen.bmj

Discrepancies between routine sacroiliac joint MRI reporting and current expert recommendations in patients with spondyloarthritis

Background Sacroiliac joint (SIJ) MRI is commonly used in diagnosing spondyloarthritis (SpA). Current Assessment of SpondyloArthritis International Society (ASAS) recommendations on reporting SIJ MRIs ...